WO2001033217A2 - Monitoring the activity of factor xa inhibitors - Google Patents

Monitoring the activity of factor xa inhibitors Download PDF

Info

Publication number
WO2001033217A2
WO2001033217A2 PCT/EP2000/010646 EP0010646W WO0133217A2 WO 2001033217 A2 WO2001033217 A2 WO 2001033217A2 EP 0010646 W EP0010646 W EP 0010646W WO 0133217 A2 WO0133217 A2 WO 0133217A2
Authority
WO
WIPO (PCT)
Prior art keywords
plasma
fxa
factor
inhibitor
clotting time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/010646
Other languages
French (fr)
Other versions
WO2001033217A3 (en
Inventor
Valeria Chu Fung-Hwei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930535.1A external-priority patent/GB9930535D0/en
Priority to AU15157/01A priority Critical patent/AU1515701A/en
Priority to MXPA02003693A priority patent/MXPA02003693A/en
Priority to CA2389747A priority patent/CA2389747C/en
Priority to EP00977438A priority patent/EP1230382B1/en
Priority to AT00977438T priority patent/ATE267876T1/en
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to IL14939800A priority patent/IL149398A0/en
Priority to JP2001535051A priority patent/JP4463460B2/en
Priority to DE60011128T priority patent/DE60011128T2/en
Publication of WO2001033217A2 publication Critical patent/WO2001033217A2/en
Publication of WO2001033217A3 publication Critical patent/WO2001033217A3/en
Priority to US10/125,627 priority patent/US7220553B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/4609—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates from reptiles
    • G01N2333/4613—Snake venom
    • G01N2333/4616—Snake venom from Russell's viper
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96444—Factor X (3.4.21.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Definitions

  • This invention is directed to measuring Factor Xa activity. Such activity can be measured using blood clotting time or chromogenic substrates.
  • the instant invention concerns assay methods for measuring the activity of FXa inhibitors. More particularly, the present invention concerns the use of Russell's viper venom (hereinafter "RVV-X") to induce the individual's endogenous FXa activity and measure the effect of FXa inhibitors.
  • RVV-X Russell's viper venom
  • the methods for measuring FXa activity in plasma are by clotting time and by chromogenic methodology.
  • FXa direct Factor Xa
  • the present invention addresses the problem of monitoring the safety and efficacy of direct FXa inhibitors.
  • the methods of the present invention can be used in all species for monitoring the safety and efficacy of intravenous or orally active FXa inhibitors. It is believed the methods of the present invention could also be used to measure the safety and efficacy of thrombin inhibitors and indirect FXa inhibitors such as anticoagulants for factors upstream of the coagulation cascade and heparin, more particularly low molecular weight heparin. The methods could be used for predicting the prothrombotic state of a patient.
  • RW-X Russell's viper venom
  • the invention achieves the object by a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a patient, who has received a FXa inhibitor, an anticoagulant, an antithrombotic agent, or any combination thereof, b) adding a solution of Russell's viper venom to the plasma sample and c) measuring clotting time or a chromogenic change.
  • Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) providing Factor X deficient plasma sample of the same species to be used to make serial dilutions of the normal plasma sample, c) adding a solution of Russell's viper venom to the plasma samples defined in a) and b), d) comparing the clotting time measured for the plasma sample from a mammal with the clotting time measured for the plasma samples diluted with Factor X deficient plasma, e) constructing a standard curve of % FXa activity (proportional to the normal plasma content) and measuring clotting time prolongation, f) knowing the clotting time of an individual, who has received FXa inhibitor treatment, and obtaining the % residual FXa activity or % FXa inhibition from the standard curve.
  • Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control normal plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom to plasma samples defined in b), d) comparing the clotting time measured for the plasma sample without Factor
  • a mammal is a human being or an animal such as cattle, sheep, rabbit, mouse or rat.
  • a Factor Xa inhibitor is a compound which is an inhibitor of the blood clotting enzymes, especially factor Xa.
  • patient means a human or a mammal.
  • Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors by measuring the residual FXa activity chromogenically, comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control normal plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom to plasma samples defined in b), d) comparing the FXa activity measured for the plasma sample without Factor Xa inhibitor with the residual FXa activity measured for the plasma samples with added Factor Xa inhibitor, e) constructing a standard curve of dose-dependent inhibition of RW-X induced by FXa inhibitor, f) by using the standard curve the concentration of FXa inhibitor in patient at various time points during the FXa inhibitor treatment could be estimated.
  • Another object of the invention is to reduce or minimize variations in measurement of the clotting time due to the handling of the plasma samples. This is achieved by adding cephalin to the plasma samples.
  • a preferred cephalin source is from rabbit brain.
  • a preferred chromogenic compound for determining the FXa activity is Spectrozyme Fxa ®. Other FXa chromogenic substrates can also be used.
  • the method according to the invention is preferably performed in a buffer having a pH from 7 to 8.
  • a preferred buffer is a tris(hydroxymethyl)aminomethan buffer (Tris), containing sodium chloride (NaCI) and polyethylene glycol-8000 (PEG-8000).
  • Preferred concentrations are from 10 mM to 200 mM, from 20 mM to 600 mM, and from 0.02% to 1 % for Tris, NaCI, and PEG- 8000, respectively.
  • Another object of the invention is to provide a kit for using the method according to the invention for a diagnostic assay for FXa inhibitor determination.
  • Another object of the invention is the use of the method according to the invention for measuring the activity of a Factor Xa inhibitor.
  • a particularly preferred Fxa inhibitor is methyl-3-(4 ' -N-oxopyhdylphenoyl)-3-methyl-2-(m-amidinobenzyl)-propionate.
  • the RWT protocol is useful for measuring RW-X induced FXa activity in plasma by clotting time.
  • the second protocol, the RWC protocol is useful for measuring RW-X induced FXa activity in plasma by chromogenic methodology.
  • RWT showed dose-dependent prolongation of clotting time by FXa inhibitors.
  • RWC showed dose-dependent FXa inhibition by FXa inhibitors. Both methods were successfully used to discriminate varying concentrations of FXa inhibitors in ex vivo plasma samples taken from human patients.
  • FXa buffer 0.05M Tris, 0.15M NaCI, 0.1 % PEG-8000, pH7.5 add 6.06g Tris, 8.77g NaCI, 1.0g PEG-8000 to 800mL H2O adjust pH to pH 7.5 using concentrated HCI. Fill up to 1 L with H2O
  • RPR Dose-dependent clotting time prolongation curve from the compound methyl-3-(4 ' -N- oxopyridylphenoyl)-3-methyl-2-(m-amidinobenzyl)-propionate (hereinafter "RPR") or the trifluoroacetate salt of RPR:
  • HCI fill up to 1 L with H2O RW-X Add 44 ⁇ l of PEG-Ca ++ buffer to 50 ⁇ l of RW-X
  • Spectrozyme FXa® 1.6 mM Add 0.8 ml of 10 mM stock to 4.2 ml of PEG-Ca working solution: buffer.
  • RW-X induced clotting time (RWT) assay could be conveniently used for monitoring the effect of RPR on patient's endogenous plasma FXa.
  • FXa buffer 0.05M Tris, 0.15M NaCI, 0.1 % PEG-8000, pH7.5 add 6.06g Tris, 8.77g NaCI, 1 .0g PEG-8000 to 800mL H O adjust to pH 7.5 using ⁇ 2ml of concentrated HCI. fill up to 1 L with H2O
  • Predose plasma 1. Add 0.2 ml FXa buffer, 0.1 ml predose plasma to the cuvette normal RWT then 0.1 ml of RW-Ca-Cephalin. (Final concentrations of RW-
  • X and Cephalin are 0.0625 ⁇ g/ml and 0.2 mg/ml, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a method of monitoring the effect of a direct of indirect Factor Xa inhibitors comprising the steps of collecting a plasma sample from a patient, adding a solution of Russell's viper venom to the plasma sample and measuring the clotting time or the residual FXa activity chromogenically.

Description

USE OF RUSSELL'S VIPER VENOM-INDUCED PLASMA FACTOR Xa ACTIVITY TO MONITOR THE ACTIVITY OF FACTOR Xa INHIBITORS
This invention is directed to measuring Factor Xa activity. Such activity can be measured using blood clotting time or chromogenic substrates. The instant invention concerns assay methods for measuring the activity of FXa inhibitors. More particularly, the present invention concerns the use of Russell's viper venom (hereinafter "RVV-X") to induce the individual's endogenous FXa activity and measure the effect of FXa inhibitors. The methods for measuring FXa activity in plasma are by clotting time and by chromogenic methodology.
Assays such as APTT and PT have been used before to measure blood clotting time. Such assays, however, are not sensitive to detect dosage differences in administration of direct Factor Xa (hereinafter "FXa") inhibitors.
The present invention addresses the problem of monitoring the safety and efficacy of direct FXa inhibitors. The methods of the present invention can be used in all species for monitoring the safety and efficacy of intravenous or orally active FXa inhibitors. It is believed the methods of the present invention could also be used to measure the safety and efficacy of thrombin inhibitors and indirect FXa inhibitors such as anticoagulants for factors upstream of the coagulation cascade and heparin, more particularly low molecular weight heparin. The methods could be used for predicting the prothrombotic state of a patient. In the endeavor to provide improved assay methods for measuring the activity of FXa inhibitors, it has now been found that the same can be achieved by the use of Russell's viper venom (hereinafter "RW-X") to measure prolongation of clotting time produced by the activity of FXa inhibitors.
The invention, as it is explained in the claims, achieves the object by a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a patient, who has received a FXa inhibitor, an anticoagulant, an antithrombotic agent, or any combination thereof, b) adding a solution of Russell's viper venom to the plasma sample and c) measuring clotting time or a chromogenic change.
Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) providing Factor X deficient plasma sample of the same species to be used to make serial dilutions of the normal plasma sample, c) adding a solution of Russell's viper venom to the plasma samples defined in a) and b), d) comparing the clotting time measured for the plasma sample from a mammal with the clotting time measured for the plasma samples diluted with Factor X deficient plasma, e) constructing a standard curve of % FXa activity (proportional to the normal plasma content) and measuring clotting time prolongation, f) knowing the clotting time of an individual, who has received FXa inhibitor treatment, and obtaining the % residual FXa activity or % FXa inhibition from the standard curve.
Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control normal plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom to plasma samples defined in b), d) comparing the clotting time measured for the plasma sample without Factor
Xa inhibitor with the clotting time measured for the plasma samples with added Factor Xa inhibitor, e) constructing a dose-dependent clotting time prolongation curve and determining the concentration of a FXa inhibitor required to prolong the clotting time twice longer than the control plasma clotting time.
A mammal is a human being or an animal such as cattle, sheep, rabbit, mouse or rat. A Factor Xa inhibitor is a compound which is an inhibitor of the blood clotting enzymes, especially factor Xa. The term "patient" means a human or a mammal.
Another object of the invention is a method of monitoring the effect of Factor Xa inhibitors by measuring the residual FXa activity chromogenically, comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control normal plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom to plasma samples defined in b), d) comparing the FXa activity measured for the plasma sample without Factor Xa inhibitor with the residual FXa activity measured for the plasma samples with added Factor Xa inhibitor, e) constructing a standard curve of dose-dependent inhibition of RW-X induced by FXa inhibitor, f) by using the standard curve the concentration of FXa inhibitor in patient at various time points during the FXa inhibitor treatment could be estimated.
Another object of the invention is to reduce or minimize variations in measurement of the clotting time due to the handling of the plasma samples. This is achieved by adding cephalin to the plasma samples. A preferred cephalin source is from rabbit brain. A preferred chromogenic compound for determining the FXa activity is Spectrozyme Fxa ®. Other FXa chromogenic substrates can also be used. The method according to the invention is preferably performed in a buffer having a pH from 7 to 8. A preferred buffer is a tris(hydroxymethyl)aminomethan buffer (Tris), containing sodium chloride (NaCI) and polyethylene glycol-8000 (PEG-8000). Preferred concentrations are from 10 mM to 200 mM, from 20 mM to 600 mM, and from 0.02% to 1 % for Tris, NaCI, and PEG- 8000, respectively.
Another object of the invention is to provide a kit for using the method according to the invention for a diagnostic assay for FXa inhibitor determination.
Another object of the invention is the use of the method according to the invention for measuring the activity of a Factor Xa inhibitor. A particularly preferred Fxa inhibitor is methyl-3-(4'-N-oxopyhdylphenoyl)-3-methyl-2-(m-amidinobenzyl)-propionate. In the examples it is shown that the RWT protocol, is useful for measuring RW-X induced FXa activity in plasma by clotting time. The second protocol, the RWC protocol, is useful for measuring RW-X induced FXa activity in plasma by chromogenic methodology. RWT showed dose-dependent prolongation of clotting time by FXa inhibitors. RWC showed dose-dependent FXa inhibition by FXa inhibitors. Both methods were successfully used to discriminate varying concentrations of FXa inhibitors in ex vivo plasma samples taken from human patients.
The method according to the invention is described in detail in the examples which follow
Example 1
Russell's viper venom-induced Clotting Time (RWT) Protocol
Reagents: FXa buffer: 0.05M Tris, 0.15M NaCI, 0.1 % PEG-8000, pH7.5 add 6.06g Tris, 8.77g NaCI, 1.0g PEG-8000 to 800mL H2O adjust pH to pH 7.5 using concentrated HCI. Fill up to 1 L with H2O
RW-X: Enzyme Research Lab.
Dilute to 1 mg/ml with FXa buffer then 1/400 in the same buffer.
RW-X working 2ml of 1/400 RW-X + 18 ml of 0.0035 M CaCl2* solution Concentration of RW-X at this point is 0.25 μg/ml.
(RW-Ca): FX-deficient American Diagnostica Inc. plasma
Procedure: All the reagents should be kept at 4°C (on ice-water mixture), before use. Standard 1. Make 2-fold serial dilutions of normal pooled plasma or patient's plasma with FX-deficient plasma from 1 ~ 1/256 2. Add 0.2 ml FXa buffer, 0.1 ml plasma dilution to the cuvette then 0.1 ml of RW-Ca (MLA-800 clotter add this reagent automatically). 3. Measure clotting time.
4. Construct standard curve.
Dose- dependent clotting time prolongation curve from the compound methyl-3-(4'-N- oxopyridylphenoyl)-3-methyl-2-(m-amidinobenzyl)-propionate (hereinafter "RPR") or the trifluoroacetate salt of RPR:
1. Add 0.1 ml FXa buffer, 0.1 ml serial dilution of RPR, 0.1 ml normal pooled or patient's plasma to the cuvette then 0.1 ml of RW-Ca (MLA-800 clotter add this reagent automatically).
2. Measure clotting time.
3. Construct the dose-dependent clotting time prolongation curve.
4. Calculate concentration for 2xRWT
Example 2
Russell's viper venom-induced FXa in plasma measured chromogenically (RWC) Protocol RWC ASSAY RW-induced FXa activity in plasma measured chromogenically. A) Reagents PEG-Ca++buffer: 0.05M Tris, 0.15M NaCI, 0.01 M CaCl2, 0.1 % PEG-8000, pH 7.50
Add 6.06g Tris, 8.77g NaCI, 1g PEG-8000, 1.47 g CaCl2.
2 H2O to 800ml H2O adjust to pH 7.5 using concentrated
HCI, fill up to 1 L with H2O RW-X Add 44 μl of PEG-Ca++ buffer to 50 μl of RW-X
(Russell's' Viper Venom): stock (Enzyme Research Labs, 1.88 mg/ml) to prepare
1 mg/ml solution, keep on ice at all times.
Dilute 1 mg/ml stock to 1/10 → 1/10→% (=1/400).
Dilutions are made in PEG-CAE Buffer.
Substrate Spectrozyme Dissolve 50μ mole of Spectozyme FXa, American FXa®: Diagnostic, in 5 ml sterile water to make a 10 mM stock solution. Spectrozyme FXa® 1.6 mM Add 0.8 ml of 10 mM stock to 4.2 ml of PEG-Ca working solution: buffer.
B) Procedure:
1. Add the reagents to the microtiter plates or test tubes in the following order:
Reagent Sample Control 1 Control 2
1 . PEG-Ca++ buffer 120 μl 120 μl 145 μl
2. control plasma - 5 μl 5 μl
3. clinical samples (plasma) 5 μl - -
4. Spectrozyme FXa® 1.6 mM 50 μl 50 μl 50 μl
5. RW-X (1 mg/ml) 1/400 dilution 25 μl 25 μl -
2. Follow the reaction kinetically for 5 min.
C) Calculation: Measure the initial velocity, however, ignore the lag phase. In general measure the initial rate of the linear portion of the time course. Use initial rates of clinical samples at different time points and then compared to the pre- dosing control to calculate % inhibition.
Various concentrations of the compound RPR spiked in plasma were assayed for PT,
APTT and PWT prolongation. The results in Table 1 suggest that RWT is the most sensitive indicator among the three clotting time assays for the effect of the compound
RPR, as a FXa inhibitor.
RW-X induced clotting time (RWT) assay could be conveniently used for monitoring the effect of RPR on patient's endogenous plasma FXa.
Table 1 :
Figure imgf000008_0001
Example 3 Russell's viper venom-induced Clotting Time (RWT) Protocol (II)
Reagents: FXa buffer: 0.05M Tris, 0.15M NaCI, 0.1 % PEG-8000, pH7.5 add 6.06g Tris, 8.77g NaCI, 1 .0g PEG-8000 to 800mL H O adjust to pH 7.5 using ~ 2ml of concentrated HCI. fill up to 1 L with H2O
RW-X: Enzyme Research Lab.
Dilute to 1 mg/ml with FXa buffer then 1/200 in the same buffer. 2mi of 1/200 RW-X + 18 ml of 0.035 M CaCl2, final concentration of RW-X at this point is 0.5 μg/ml. Rabbit brain Centerchem Cephalin
Reconstitute with 3.125 ml of 0.035 M CaCl2 in FXa buffer to a final concentration of 1 .6 mg/ml.
RW-X RB Equal volume of 0.5 μg/ml RW-X mixed with equal volume of
Cephalin working 1.6 mg/ml of rabbit brain Cephalin. solution The final concentrations of RW-X and Cephalin in the reagent
(RW-Ca- reservoir at this stage are 0.25 μg/ml and 0.8 mg/ml,
Cephalin): respectively.
Procedure: All the reagents should be kept at 4 ° C (on ice-water mixture), before use.
Predose plasma 1. Add 0.2 ml FXa buffer, 0.1 ml predose plasma to the cuvette normal RWT then 0.1 ml of RW-Ca-Cephalin. (Final concentrations of RW-
X and Cephalin are 0.0625 μg/ml and 0.2 mg/ml, respectively)
2 Measure clotting time.
Result: Calculate fold-change of RWT
Effect of rabbit brain cephalin on RWT
RW-induced plasma (Pooled GK plasma and donors DN, RB, TD) clotting time with added dilutions of cephalin (n = 2)
Figure imgf000010_0001
Conclusion: RWT variations due to the sample handling could be reduced by addition of -0.2 mg/ml of rabbit brain cephalin in the reaction mixture.

Claims

WHAT IS CLAIMED IS:
1. A method of monitoring the effect of Factor Xa (FXa) inhibitors comprising the steps of : a) collecting a plasma sample from a patient, who has received a FXa inhibitor, an anticoagulant, an antithrombotic agent, or any combination thereof, b) adding a solution of Russell's viper venom to the plasma sample and c) measuring clotting time or a chromogenic change.
2. A method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) providing a Factor X deficient plasma sample of the same species to be used to make serial dilutions of the normal plasma sample, c) adding a solution of Russell's viper venom to the plasma samples defined in a) and b), d) comparing the clotting time measured for the plasma sample with the clotting time measured for the plasma samples diluted with Factor X deficient plasma, e) constructing a standard curve of % FXa activity (proportional to the normal plasma content) and clotting time prolongation, f) knowing the clotting time of the mammal, which received FXa inhibitor treatment,
% residual FXa activity or % FXa inhibition is obtained from the standard curve.
3. A method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control normal plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom to plasma samples defined in b),d) comparing the clotting time measured for the plasma sample without Factor Xa inhibitor with that plasma samples with added Factor Xa inhibitor, e) constructing a dose-dependent clotting time prolongation curve and determining the concentration of a FXa inhibitor required to prolong the clotting time twice longer than the control plasma clotting time.
4. A method of monitoring the effect of Factor Xa inhibitors comprising the steps of: a) collecting a plasma sample from a mammal, b) dividing said plasma sample into portions, saving one portion as the control plasma and adding serial dilutions of Factor Xa inhibitor to other portions, c) adding a solution of Russell's viper venom (RW-X) to plasma samples defined in b), d) comparing the FXa activity measured for the control plasma with the residual FXa activity measured for the other plasma samples with added Factor Xa inhibitor, e) constructing a standard curve of dose-dependent inhibition of RW-X induced by FXa inhibitor, f) the concentration of FXa inhibitor is estimated by using the standard curve.
5. A method as claimed in any of claims 1 to 4, wherein the residual FXa activity is measured chromogenically.
6. A method as claimed in any of claims 1 to 5, wherein cephalin is added to the plasma samples.
7. A method as claimed in any of claims 1 to 6, wherein the plasma samples where incubated in a buffer having a pH from 7 to 8.
8. The use of a method as claimed in any of claims 1 to 7 for the preparation of a diagnostic assay for FXa inhibitor determination.
9. The use of a method as claimed in any of claims 1 to 7 for the determination of the activity of a direct or indirect Factor Xa inhibitor.
10. The use as claimed in claim 9, wherein the FXa inhibitor is methyl-3-(4'-N- oxopyridylphenoyl)-3-methyl-2-(m-amidinobenzyl)-propionate.
PCT/EP2000/010646 1999-11-02 2000-10-28 Monitoring the activity of factor xa inhibitors Ceased WO2001033217A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE60011128T DE60011128T2 (en) 1999-11-02 2000-10-28 MONITORING THE ACTIVITY OF FACTOR XA INHIBITORS
JP2001535051A JP4463460B2 (en) 1999-11-02 2000-10-28 Use of Russell's viper snake venom-induced plasma factor Xa activity to monitor the activity of factor Xa inhibitors
CA2389747A CA2389747C (en) 1999-11-02 2000-10-28 Use of russell's viper venom-induced plasma factor xa activity to monitor the activity of factor xa inhibitors
EP00977438A EP1230382B1 (en) 1999-11-02 2000-10-28 Monitoring the activity of factor xa inhibitors
AT00977438T ATE267876T1 (en) 1999-11-02 2000-10-28 MONITORING THE ACTIVITY OF FACTOR XA INHIBITORS
AU15157/01A AU1515701A (en) 1999-11-02 2000-10-28 Use of russell's viper venom-induced plasma factor xa activity to monitor the activity of factor xa inhibitors
IL14939800A IL149398A0 (en) 1999-11-02 2000-10-28 USE OF RUSSELL'S VIPER VENOM-INDUCED PLASMA FACTOR Xa ACTIVITY TO MONITOR THE ACTIVITY OF FACTOR Xa INHIBITORS
MXPA02003693A MXPA02003693A (en) 1999-11-02 2000-10-28 Monitoring the activity of factor xa inhibitors.
US10/125,627 US7220553B2 (en) 1999-11-02 2002-04-18 Use of Russell's viper venom-induced plasma factor Xa activity to monitor the activity of factor Xa inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16316199P 1999-11-02 1999-11-02
US60/163,161 1999-11-02
GB9930535.1 1999-12-23
GBGB9930535.1A GB9930535D0 (en) 1999-12-23 1999-12-23 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/125,627 Continuation US7220553B2 (en) 1999-11-02 2002-04-18 Use of Russell's viper venom-induced plasma factor Xa activity to monitor the activity of factor Xa inhibitors

Publications (2)

Publication Number Publication Date
WO2001033217A2 true WO2001033217A2 (en) 2001-05-10
WO2001033217A3 WO2001033217A3 (en) 2001-11-29

Family

ID=26316147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010646 Ceased WO2001033217A2 (en) 1999-11-02 2000-10-28 Monitoring the activity of factor xa inhibitors

Country Status (11)

Country Link
US (1) US7220553B2 (en)
EP (1) EP1230382B1 (en)
JP (1) JP4463460B2 (en)
AT (1) ATE267876T1 (en)
AU (1) AU1515701A (en)
CA (1) CA2389747C (en)
DE (1) DE60011128T2 (en)
ES (1) ES2222250T3 (en)
IL (1) IL149398A0 (en)
MX (1) MXPA02003693A (en)
WO (1) WO2001033217A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108982865A (en) * 2018-08-16 2018-12-11 上海原科实业发展有限公司 A kind of thrombelastogram method heparin immue quantitative detection reagent box and preparation method thereof
US10501773B2 (en) 2014-07-31 2019-12-10 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0705049B1 (en) * 2007-12-28 2019-02-26 Embraco Indústria De Compressores E Soluções Em Refrigeração Ltda GAS COMPRESSOR MOVED BY A LINEAR MOTOR, HAVING AN IMPACT DETECTOR BETWEEN A CYLINDER AND PISTON, DETECTION METHOD AND CONTROL SYSTEM
EP2316931B1 (en) * 2009-10-30 2016-12-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Polymer-coupled peptidases
US20110136779A1 (en) * 2009-11-23 2011-06-09 Milner Peter G Methods for stroke reduction in atrial fibrillation patients
US9549912B2 (en) 2009-11-23 2017-01-24 Armetheon, Inc. Methods for treating atrial fibrillation
US20110144199A1 (en) * 2009-11-23 2011-06-16 Milner Peter G Methods for treating atrial fibrillation
EP2484775A1 (en) * 2011-02-07 2012-08-08 Siemens Healthcare Diagnostics Products GmbH Heparin-insensitive method for detecting direct clotting factor inhibitors
ES3020087T3 (en) 2020-09-21 2025-05-21 Instr Laboratory Co Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
CN114681597A (en) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 Application of viper venom hemocoagulase in preparation of drugs for reversing anticoagulation of coagulation factor Xa inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189646A (en) * 1982-04-01 1983-11-05 Canon Inc magnetic toner
US4946775A (en) * 1985-09-05 1990-08-07 Yin E Thye Composition, kit and method for assaying heparin and a method for making the composition
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5187155A (en) * 1989-06-23 1993-02-16 Board Of Regents, The University Of Texas System Anticoagulant peptides
US6103888A (en) * 1992-07-17 2000-08-15 Panorama Research, Inc. Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
DK0906094T3 (en) 1996-01-02 2003-10-20 Aventis Pharma Inc Substituted N - [(aminoiminomethyl or aminomethyl) phenyl] propylamides
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRECHER ARTHUR S ET AL: "Coagulation protein function: IV. Effect of acetaldehyde upon factor X and factor Xa, the proteins at the gateway to the common coagulation pathway." ALCOHOL, vol. 13, no. 6, 1996, pages 539-545, XP001006020 ISSN: 0741-8329 *
GONG Y Y ET AL: "Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 10, no. 3, February 2000 (2000-02), pages 217-221, XP004188820 ISSN: 0960-894X *
JESTY J: "ANALYSIS OF THE GENERATION AND INHIBITION OF ACTIVATED COAGULATION FACTOR-X IN PURE SYSTEMS AND IN HUMAN PLASMA" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 261, no. 19, 1986, pages 8695-8702, XP001006017 ISSN: 0021-9258 *
RAO L VIJAYA MOHAN ET AL: "Antibody induced acute factor X deficiency: Clinical manifestations and properties of the antibody." THROMBOSIS AND HAEMOSTASIS, vol. 72, no. 3, 1994, pages 363-371, XP001006019 ISSN: 0340-6245 *
VAN WIJK E M ET AL: "MECHANIZED AMIDOLYTIC TECHNIQUE FOR DETERMINATION OF FACTOR-X AND FACTOR-X ANTIGEN AND ITS APPLICATION TO PATIENTS BEING TREATED WITH ORAL ANTI COAGULANTS" CLINICAL CHEMISTRY, vol. 26, no. 7, 1980, pages 885-890, XP002169624 ISSN: 0009-9147 *
WALENGA J M ET AL: "ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES" THROMBOSIS RESEARCH, vol. 46, no. 2, 1987, pages 187-198, XP001006018 ISSN: 0049-3848 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501773B2 (en) 2014-07-31 2019-12-10 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
US10954549B2 (en) 2014-07-31 2021-03-23 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
CN108982865A (en) * 2018-08-16 2018-12-11 上海原科实业发展有限公司 A kind of thrombelastogram method heparin immue quantitative detection reagent box and preparation method thereof
CN108982865B (en) * 2018-08-16 2021-05-11 上海原科实业发展有限公司 Thrombus elastography heparin quantitative detection kit and preparation method thereof

Also Published As

Publication number Publication date
JP4463460B2 (en) 2010-05-19
MXPA02003693A (en) 2003-10-14
DE60011128T2 (en) 2005-07-07
IL149398A0 (en) 2002-11-10
US20030049704A1 (en) 2003-03-13
CA2389747A1 (en) 2001-05-10
EP1230382B1 (en) 2004-05-26
JP2003513280A (en) 2003-04-08
DE60011128D1 (en) 2004-07-01
EP1230382A2 (en) 2002-08-14
ES2222250T3 (en) 2005-02-01
ATE267876T1 (en) 2004-06-15
AU1515701A (en) 2001-05-14
CA2389747C (en) 2011-05-03
WO2001033217A3 (en) 2001-11-29
US7220553B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
US6566140B2 (en) Inhibition of coagulation in blood and blood products
Al Dieri et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding
JP3047120B2 (en) Quantitative blood clotting assay for activator VII
Goldenberg et al. A new global assay of coagulation and fibrinolysis
JP2003517610A (en) Hematological assays and reagents
JPH07501217A (en) How to diagnose blood clotting disorders
Kluft Occurrence of Cl inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity
EP1230382B1 (en) Monitoring the activity of factor xa inhibitors
EA000673B1 (en) Factor v ratio blood test for susceptibility to thromboembolism
Murray et al. Activated protein C resistance, thrombophilia, and inflammatory bowel disease
Colucci et al. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential
Fritsch et al. Thrombin generation in factor VIII‐depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor
US4139415A (en) In vitro method of determining the biological activity of factor Xa inhibitor in blood
US5705396A (en) Additive for diagnostic tests for determination of the coagulability of blood, method of reducing the influencing of diagnostic tests by heparin and the use of metal salts for these purposes
EP0440775B1 (en) Factor ix chromogenic assay
Curvers et al. Effects of (pre-) analytical variables on activated protein C resistance determined via a thrombin generation-based assay
US6426192B1 (en) Method for the functional detection of disorders in the protein C system
JPH04350560A (en) Functional measuring method for activity of protein s
ES2217739T3 (en) IMPROVED BLOOD COAGULATION TEST.
US5114845A (en) Assays for plasminogen activator inhibitor and soluble fibrin
Giddings et al. Laboratory support in the diagnosis of coagulation disorders
Scully The use of an automated analyzer in the evaluation of antithrombin III and heparin
Patrassi et al. A DIC-like picture on plasma and ascitic fluid of cirrhotic patients
Rylatt et al. Detecting APC-resistant factor V: a functional method without plasma dilution
Antovic Determination of the overall haemostasis potential and fibrin gel permeability: method development and application in research and in clinical materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003693

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10125627

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000977438

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 149398

Country of ref document: IL

Ref document number: 15157/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 535051

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2389747

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000977438

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000977438

Country of ref document: EP